“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
Subscribe To Our Newsletter & Stay Updated
